Atlas Venture Associates IX, L.P. 4
4 · Surface Oncology, Inc. · Filed Apr 23, 2018
Insider Transaction Report
Form 4
Atlas Venture Fund IX, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2018-04-23+3,181,817→ 4,545,453 total - Purchase
Common Stock
2018-04-23$15.00/sh+100,000$1,500,000→ 4,645,453 total - Conversion
Series A Preferred Stock
2018-04-23−7,000,000→ 0 total→ Common Stock (3,181,817 underlying)
Footnotes (2)
- [F1]The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date.
- [F2]The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.